These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 9933344

  • 1. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M, Ferrari M, Chinol M, Stabin MG, Grana C, Prisco G, Robertson C, Tosi G, Paganelli G.
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [Abstract] [Full Text] [Related]

  • 2. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [Abstract] [Full Text] [Related]

  • 3. Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting.
    Chinol M, Paganelli G, Sudati F, Meares C, Fazio F.
    Nucl Med Commun; 1997 Feb; 18(2):176-82. PubMed ID: 9076775
    [Abstract] [Full Text] [Related]

  • 4. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 5. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 7. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [Abstract] [Full Text] [Related]

  • 8. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
    Cremonesi M, Ferrari M, Chinol M, Bartolomei M, Stabin MG, Sacco E, Fiorenza M, Tosi G, Paganelli G.
    Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR.
    Crit Rev Oncol Hematol; 2001 Dec; 39(1-2):181-94. PubMed ID: 11418315
    [Abstract] [Full Text] [Related]

  • 10. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 11. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 12. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
    Domingo RJ, Reilly RM.
    Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
    [Abstract] [Full Text] [Related]

  • 13. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 14. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
    Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M.
    Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ.
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [Abstract] [Full Text] [Related]

  • 16. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
    Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM.
    J Nucl Med; 2000 Jan; 41(1):131-40. PubMed ID: 10647616
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM, Bäck TA, Fisher DR, Press OW.
    PLoS One; 2015 Jan; 10(3):e0120561. PubMed ID: 25785845
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
    Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G, Chinol M.
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
    [Abstract] [Full Text] [Related]

  • 19. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 20. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.
    Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U.
    Eur J Nucl Med; 1999 Apr; 26(4):348-57. PubMed ID: 10199940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.